Status: Recruiting

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Participants needed: 15

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jul 31, 2026Locations: 1

Eligibility criteria

Histologically confirmed leiomyosarcoma (any site of origin). [+17]

Participants who are receiving any other investigational agents or have received... [+12]

Status: Not yet recruiting

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV).

Participants needed: 30

Trial details

Phase: Phase 1Age: 18-50Biological sex: FemaleType: InterventionalSponsor: Changchun GeneScience Pharmaceutical Co., Ltd.Updated: Jun 23, 2026Locations: 7

Eligibility criteria

Women of childbearing age aged 18-50 years (inclusive of the cut-off values, as... [+7]

Those currently suffering from any acute infection of the urinary or reproductiv... [+20]

Open Label

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)